An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Robin, Alan L., M.D.
• Treatments: Antihypertensive Agents; Bimatoprost; Latanoprost; Travoprost

Criteria

Inclusion Criteria:

• Currently using one or two topical ocular hypotensive medications

Exclusion Criteria:

• Hypersensitivity to any component of medication